Dr. Neal D. Shore

HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.

Neal D. Shore, 2020, ASCO Annual Meeting

Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.

Neal D. Shore, 2022, ASCO Annual Meeting

Phase Ib study: APL-1202 (APL) in combination with Bacillus Calmette-Guerin (BCG) in recurrent non-muscle invasive bladder cancer (NMIBC).

Neal D. Shore, 2020, ASCO Annual Meeting

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).

Neal D. Shore, 2020, ASCO Annual Meeting

Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.

Neal D. Shore, 2020, ASCO Annual Meeting

DaroACT: Darolutamide and enzalutamide effects on physical and neurocognitive function and daily activity in patients with castration-resistant prostate cancer (CRPC).

Neal D. Shore, 2020, ASCO Annual Meeting

TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).

Neal D. Shore, 2020, ASCO Annual Meeting

Pembrolizumab Plus Enzalutamide in Abiraterone-Pretreated Patients with Metastatic Castration-Resistant Prostate Cancer: Updated Results from Keynote-365 Cohort C

Yu, EY, P Fong, JM Piulats, L Appleman, H Conter, S Feyerabend, N Shore, G Gravis, B Laguerre, H Gurney, M Retz, E Romano, L Mourey, JS de Bonno, A Kam, U Emmenegger, H Wu, C Poehlein, and W Berry, 2020, American Urological Association Annual Meeting

A multicenter phase IIb trial to evaluate the efficacy and tolerability of ModraDoc006/r in subjects with metastatic castration-resistant prostate cancer (mCRPC), suitable for treatment with a taxane (NCT04028388)

Vaishampayan, UN, EJ De Wit, ND Shore, R Dreicer, DJ George, RV Boccia, BD Curti, L Geczi, T Csõszi, and NJ Vogelzang, 2020, Genitourinary Cancers Symposium

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC)

Taplin, M-E, M Gleave, CP Evans, E Efstathiou, PW Kantoff, A Ross, ND Shore, A Briganti, BA Hadaschik, A Heidenreich, OB Rooney, SK Tian, L Wetherhold, W Xu, S Cheng, SD Brookman-May, A Lopez-Gitlitz, and AS Kibel, 2020, Genitourinary Cancers Symposium

Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Shore, ND, OA Sartor, CN Sternberg, F Saad, BF Tombal, K Miller, J Kalinovsky, X Jiao, K Tangirala, and CS Higano, 2020, Genitourinary Cancers Symposium

An open-label phase Ib study of ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide

Shore, ND, R Patel, R Xu, PS Multani, Michael J. Morris, and W Abida, 2020, Genitourinary Cancers Symposium

Review of the real-world prevalence of mHSPC, nmCRPC, mCRPC, and gene alterations associated with HRR in prostate cancer (PC)

Shore, ND, L Oliver, I Shui, A Gayle, OY Wong, J Kim, S Payne, and SR Ghate, 2020, Genitourinary Cancers Symposium

Integrating comprehensive genomic profiling into the clinical management of prostate cancer patients: A single institution community practice experience

Shore, ND, J Haberberger, EA Severson, P Sathyan, P Reddy, and SH Ramkissoon, 2020, Genitourinary Cancers Symposium

Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone acetate (abi)–pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-921

Shore, ND, Mostefa Bennamoun, R Ratta, JM Piulats, B Li, C Schloss, and K Fizazi, 2020, Genitourinary Cancers Symposium

HERO Phase 3 Trial: Results Comparing Relugoliz, an Oral GNRH Receptor Antagonist, vs Leuprolide Acetate for Advanced Prostate Cancer

Shore, N, F Saad, M Cookson, DJ George, DR Saltzstein, R Tutrone, H Akaza, A Bossi, D van Veenhuyzen, B Selby, X Fan, V Kang, J Walling, and B Tombal, 2020, American Urological Association Annual Meeting

Phase 3 Results of Vicinium in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Shore, N, M O’Donnell, T Keane, MAS Jewett, GS Kulkarni, R Dickstein, F Wolk, C Dunshee, L Belkoff, RL Dillon, J Cizeau, and W Kassouf, 2020, American Urological Association Annual Meeting

Impact of Baseline Disease Volume and Prior Docetaxel Therapy on Prostate-Specific Antigen-Related Outcomes in Patients with Metastatic Hormone-Sensitive Prostate Cancer Treated with Enzalutamide Plus Androgen Deprivation Therapy

Shore, N, ED Crawford, RZ Szmulewitz, D Petrylak, J Holzbeierlein, A Villers, A Azad, A Alcaraz, B Alekseev, T Iguchi, F Gomez-Veiga, B Rosbrook, B Baron, GP Haas, A Stenzl, and AJ Armstrong, 2020, American Urological Association Annual Meeting

Prostate Cancer Active Surveillance Quality in Large Community Urology Practices

Shelton, J, E Wood, T Paivanas, P Buffington, S Ruyle, E Cohen, R Natale, B Mehlhaff, R Suh, T Bradford, A Koo, L Kwan, and N Shore, 2020, American Urological Association Annual Meeting

Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Saad, F, KN Chi, ND Shore, JN Graff, EM Posadas, BM Espina, E Zhu, A Hazra, B Bradic, S Cheng, V Hayreh, and A Rezazadeh, 2020, Genitourinary Cancers Symposium

A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC)

Ross, A, AJ Armstrong, Christopher M Pieczonka, JL Bailen, RF Tutrone, MR Cooperberg, CP Pavlovich, JF Renzulli, H Haynes, NA Sheikh, and ND Shore, 2020, Genitourinary Cancers Symposium

The association of humoral antigen spread (AgS) with cytotoxic T lymphocyte (CTL) activity after sipuleucel-T (sip-T) treatment in two phase II clinical studies: STAMP and STRIDE

Petrylak, DP, ES Antonarakis, H Kandadi, L Fong, RS Lance, T Vu, NA Sheikh, ND Shore, and CG Drake, 2020, Genitourinary Cancers Symposium

Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience

Hussain, MHA, J Mateo, SK Sandhu, K Fizazi, F Saad, ND Shore, D Olmos, C Corcoran, C Sibilla, A Kohlmann, CA Adelman, JA Elvin, CD Goessl, J Burgents, and JS De Bono, 2020, Genitourinary Cancers Symposium

Can TURBT be Avoided? Primary Chemoablation with a Reverse Thermal Gel Containing Mitomycin (UGN-102) in Patients with Low Grade Intermediate Non-Muscle Invasive Bladder Cancer

Huang, W, K Chevli, A Trainer, A Smith, D Saltzstein, Y Ehrlich, B Friiedman, R D’Anna, D Morris, B Hu, M Tyson, A Sankin, M Kates, J Linehan, D Scherr, S Kester, M Verni, K Chemie, L Karsch, A Cinman, E Seltzer, N Gabai, R Kirshoff, M Schoenberg, J Raman, and N Shore, 2020, American Urological Association Annual Meeting

Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC)

Higano, CS, F Saad, AO Sartor, K Miller, P Conti, DJ George, CN Sternberg, ND Shore, JP Sade, J Bellmunt, MR Smith, C Logothetis, F Verholen, J Kalinovsky, I Bayh, and BF Tombal, 2020, Genitourinary Cancers Symposium

Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905

Galsky, MD, A Necchi, ND Shore, F Witjes, K Nam, E Sbar, B Homet Moreno, and ER Plimack, 2020, Genitourinary Cancers Symposium

PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

De Bono, JS, K Fizazi, F Saad, ND Shore, G Roubaud, M Ozguroglu, N Penel, N Matsubara, N Mehra, G Procopio, MP Kolinsky, K Nishimura, S Feyerabend, JY Joung, NJ Vogelzang, MA Carducci, J Kang, CH Poehlein, W Wu, and MHA Hussain, 2020, Genitourinary Cancers Symposium

KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

Berry, WR, PCC Fong, JM Piulats, LJ Appleman, HJ Conter, S Feyerabend, ND Shore, G Gravis, B Laguerre, H Gurney, M Retz, E Romano, L Mourey, JS De Bono, AE Kam, U Emmenegger, Helen Wu, Charles Schloss, Christian Heinrich Poehlein, and Evan Y. Yu, 2020, Genitourinary Cancers Symposium

TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC)

Agarwal, N, ND Shore, C Dunshee, LI Karsh, A Azad, AP Fay, J Carles, B Sullivan, N Di Santo, M Elmeliegy, X Lin, RGW Quek, A Czibere, and K Fizazi, 2020, Genitourinary Cancers Symposium

Lower ut symptoms due to benign prostatic hyperplasia

Shore, N.D., ,

Z120920141

Francisco A. Myslicki, Jesse Shulman, Sharon Salenius, Neal Shore, Constantine Mantz, Eduardo Fernandez, Steven E. Finkelstein, 2015, ARS

Z050320161

Neal D. Shore, 2016, E-Cancer TV

mshoreurotoday

Neal D. Shore, 2017, LUGPA

mshore31618

Neal D. Shore, 2018, Urology Today

61520157

Myslicki FA, Salenius SA, Shore ND, Mantz CA, Fernandez E, Finkelstein SE, 2015, ACRO Annual Meeting